MHRA Clarifies UK Path for Microbiome Medicines

No microbiome-based medicine has ever been licensed in the UK, and MHRA has just told developers that the reason is not a missing regulatory pathway. On 18 August 2026 the agency published a position paper stating that microbiome-based medicinal products (MBMPs) — therapies that modulate, restore, or replace the human microbiome — already fall within the UK's existing medicines framework, and does not require new legislation before the first one can be authorised.

A category without a precedent

Microbiome-based medicines are a genuinely awkward fit for a regulatory system built around single, well-characterised molecules: a product might be a defined consortium of live bacterial strains, a broader faecal-derived preparation, or an engineered organism, and its mechanism runs through a complex, variable ecosystem rather than one active ingredient binding one target. With zero UK-licensed precedents to point to, developers have had to guess at classification and evidentiary expectations largely from first principles. MHRA's position paper is an attempt to close that gap before the first pivotal trial is designed, not after a marketing authorisation application arrives with assumptions the agency does not share.

Biological medicine, or advanced therapy

The paper's central fork is classification: MBMPs may be regulated as biological medicinal products, the same broad category covering most modern biologics, or in some cases may meet the criteria for advanced therapy medicinal products — the tier that covers gene therapies, cell therapies, and tissue-engineered products, with its own, generally more demanding manufacturing and evidence expectations. Which side of that line a given product falls on will shape years of development strategy, from the size of the chemistry-and-manufacturing package to the clinical evidence a marketing authorisation application will need. MHRA's message is that the answer depends on the product's actual characteristics, not on the novelty of the modality itself.

What developers are expected to show

• Product characterisation: defining precisely what the product contains — strain identity and composition for a defined consortium, or comparable specificity for other MBMP formats.
• Manufacturing consistency: demonstrating control over batch-to-batch variability in a product whose active substance is a living system, not a fixed chemical entity.
• Safety assessment, including antimicrobial resistance risk: a consideration specific to therapies that interact with a patient's existing microbial population.
• Robust clinical evidence: the standard bar for any UK marketing authorisation, applied to a modality with no local precedent to benchmark against.

Zero products, one clear signal

The practical offer sits at the end of the paper: MHRA is encouraging developers to engage its Innovation Office and Scientific Advice services early, before pivotal trials are locked in, to agree a proportionate development strategy and reduce investment risk. For a modality with no UK-authorised comparator, that early engagement is less a courtesy than a necessity — without it, a developer is designing a pivotal programme against a classification and evidence bar the regulator has not yet confirmed applies to their specific product.